Clinical Focus

• Cancer> Blood and Marrow Transplant
• Cancer> Hematology
• Blood and Marrow Transplantation
• Hematology

Administrative Appointments

• Medical Director, Clinical Bone Marrow Transplantation Laboratory (1990 - present)
• Division Chief, Blood and Marrow Transplant Program, Stanford University (2000 - present)

Honors and Awards

• Fellowship, Damon Runyon-Walter Winchell Cancer Fund (1988-1991)
• Fellow, Jose Carreras International Leukemia Foundation (1993-1996)
• President, International Society of Cellular Therapy (2000-2002)
• Distinguished Clinical Scientist Award, Doris Duke Foundation (2004-2009)
• President, American Society of Blood and Marrow Transplantation (2006-2007)

Professional Education

Postdoctoral Advisees

Mareike Florek,  Byung Su Kim,  Aaron Logan,  Everett Meyer,  Antonio Pierini,  Emanuela Sega

Graduate & Fellowship Program Affiliations

• Cancer Biology
• Immunology
• Medicine

Community and International Work

• Volunteer 

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities. View Full Information

Current Research Interests

Research projects in our laboratory are aimed at studying the biology of cell populations capable of inducing or suppressing graft vs host disease as well as cells capable of promoting a graft vs tumor effect. In particular we are studying:

1) The clinical utility of expanded cytotoxic cells for immunotherapy. We have developed animal models utilizing mice with severe combined immunodeficiency (SCID) which will accept human tumor cells or murine model systems of syngeneic and allogeneic transplantation. In some instances the tumor cells are transfected with the bioluminescent marker luciferase so that the tumor cell growth can be quantitatively tracked in living animals. Using these model system we are studying the clinical efficacy of the expanded cytotoxic cells.

2) The interaction between the cytotoxic effector cells and a variety of tumor cell targets is under study. The role of granzyme/perforin and fas mediated pathways as well as the cell surface molecule NKG2D in cytotoxicity is under study.

3) We are exploring the biological impact of phenotypically defined populations of regulatory T cells on graft vs host disease and graft vs tumor reactions.

4) We are utilizing bioluminescent techniques to study these complex biological processes by either labelling the tumor or effector cell populations with the light emitting luciferase gene such that small numbers of cells can be tracked non-invasively, sensively and quantitatively.

Clinical Trials

• Research Sample Repository for Allogeneic Unrelated Hematopoietic Stem Cell Transplantation Recruiting
• A Phase 3 Study of Brentuximab Vedotin (SGN-35) for Prevention of Hodgkin Lymphoma Progression (The AETHERA Trial) Recruiting
• Allogeneic HCT using Nonmyeloablative Host Conditioning with TLI & ATG vs SOC in AML Recruiting
• Allogeneic Transplantation Using TL1 & ATG for Older Patients with Hematologic Malignancies Recruiting
• Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma Recruiting

Publications

• Long-term outcome of patients with metastatic breast cancer treated with high-dose chemotherapy and transplantation of purified autologous hematopoietic stem cells. Müller AM, Kohrt HE, Cha S, Laport G, Klein J, Guardino AE, Johnston LJ, Stockerl-Goldstein KE, Hanania E, Juttner C, Blume KG, Negrin RS, Weissman IL, Shizuru JA. Biol Blood Marrow Transplant. 2012; 18 (1): 125-33
• Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Laport GG, Sheehan K, Baker J, Armstrong R, Wong RM, Lowsky R, Johnston LJ, Shizuru JA, Miklos D, Arai S, Benjamin JE, Weng WK, Negrin RS. Biol Blood Marrow Transplant. 2011; 17 (11): 1679-87
• Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response. Tomblyn MR, Ewell M, Bredeson C, Kahl BS, Goodman SA, Horowitz MM, Vose JM, Negrin RS, Laport GG. Biol Blood Marrow Transplant. 2011; 17 (7): 1051-7
• CD8+CD44(hi) but not CD4+CD44(hi) memory T cells mediate potent graft antilymphoma activity without GVHD. Dutt S, Baker J, Kohrt HE, Kambham N, Sanyal M, Negrin RS, Strober S. Blood. 2011; 117 (11): 3230-9
• Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY. Naik S, Wong R, Arai S, Brown J, Laport G, Lowsky R, Miklos D, Shizuru J, Blume K, Negrin R, Johnston L. Bone Marrow Transplant. 2011; 46 (2): 192-9